An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

China approves world's first CAR-T cell therapy for solid tumors: CARsgen's satri-cel for advanced gastric cancer

CARsgen Therapeutics has received approval from China's NMPA for satricabtagene autoleucel (satri-cel; CT041), the world's first CAR-T cell

AI-guided discovery identifies GPNMB as promising CAR T cell target for multiple cancers

Researchers developed an AI-driven framework for discovering CAR T cell therapy targets by integrating single-cell RNA sequencing data from

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus

This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce

Donor-derived stem cell memory CAR T cells show enhanced expansion and safety in post-HSCT relapse treatment

This first-in-human study (NCT01087294) investigates donor-derived CD19-CAR T cells for treating B cell malignancies relapsing after allogen

Antibody-ligand motif optimization enables multitarget switchable CAR-T therapy against solid tumors

This article presents a research study on optimizing a multitarget switchable CAR-T (sCAR-T) strategy to overcome antigenic heterogeneity an